Chera BS, Amdur RJ, Green R, et al. - Researchers intended to report the outcomes of a phase II clinical trial of de-intensified chemoradiotherapy for 114 individuals with human papillomavirus–associated oropharyngeal squamous cell carcinoma. Ten or fewer tobacco pack-years were noted in 80% of individuals. A feeding tube was required by 34% of individuals. No grade 3 or higher late adverse events were noted. Thus, in patients with human papillomavirus–associated oropharyngeal squamous cell carcinoma, clinical outcomes with a de-intensified chemoradiotherapy regimen of 60 Gy intensity-modulated radiotherapy with concurrent low-dose cisplatin were concluded as favorable. Moreover, neither neoadjuvant chemotherapy nor routine surgery is required to get favorable outcomes with de-escalation.